Your browser is no longer supported. Please, upgrade your browser.
Settings
SURF Surface Oncology, Inc. daily Stock Chart
SURF [NASD]
Surface Oncology, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.30% Shs Outstand27.98M Perf Week15.16%
Market Cap167.40M Forward P/E- EPS next Y-1.98 Insider Trans-83.38% Shs Float27.65M Perf Month5.82%
Income-28.00M PEG- EPS next Q-0.48 Inst Own86.10% Short Float1.55% Perf Quarter119.78%
Sales39.50M P/S4.24 EPS this Y-495.10% Inst Trans43.06% Short Ratio0.18 Perf Half Y96.72%
Book/sh2.92 P/B2.05 EPS next Y-130.20% ROA-20.10% Target Price10.33 Perf Year183.02%
Cash/sh3.23 P/C1.86 EPS next 5Y- ROE-38.40% 52W Range1.15 - 7.66 Perf YTD219.15%
Dividend- P/FCF- EPS past 5Y- ROI-88.70% 52W High-21.67% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low421.74% ATR0.59
Employees49 Current Ratio7.00 Sales Q/Q168.10% Oper. Margin-71.20% RSI (14)59.12 Volatility11.47% 10.17%
OptionableNo Debt/Eq0.06 EPS Q/Q583.80% Profit Margin-70.90% Rel Volume0.29 Prev Close5.91
ShortableYes LT Debt/Eq0.06 EarningsMay 12 BMO Payout- Avg Volume2.35M Price6.00
Recom1.70 SMA209.86% SMA5013.37% SMA20092.06% Volume686,181 Change1.52%
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
Aug-05-20 11:59AM  
Jun-12-20 09:45AM  
Jun-10-20 08:12PM  
May-28-20 04:10PM  
May-20-20 11:28AM  
07:15AM  
07:05AM  
May-15-20 11:46AM  
07:30AM  
May-14-20 07:30AM  
May-13-20 08:00AM  
May-12-20 06:20AM  
May-07-20 12:30PM  
Apr-23-20 08:00AM  
Mar-17-20 08:00AM  
Mar-12-20 10:39AM  
Mar-10-20 06:20AM  
Mar-06-20 11:30AM  
Feb-25-20 04:05PM  
Feb-19-20 11:30AM  
Feb-04-20 06:58AM  
Jan-28-20 07:12AM  
Jan-27-20 04:05PM  
Dec-23-19 10:24AM  
Dec-09-19 05:45PM  
Nov-26-19 11:07AM  
08:00AM  
Nov-25-19 08:00AM  
Nov-18-19 06:30AM  
Nov-12-19 07:45AM  
06:30AM  
Nov-07-19 08:00AM  
Oct-26-19 06:25PM  
Oct-07-19 07:00AM  
Sep-23-19 12:50PM  
Sep-18-19 05:55PM  
Sep-17-19 05:25PM  
Sep-03-19 04:05PM  
01:45PM  
07:00AM  
Aug-28-19 10:45AM  
Aug-27-19 08:00AM  
Aug-21-19 08:45PM  
Aug-20-19 01:15PM  
Aug-15-19 11:20PM  
Aug-14-19 08:55PM  
Aug-12-19 06:20PM  
Aug-08-19 09:05PM  
Aug-07-19 10:30PM  
09:30PM  
10:07AM  
09:05AM  
06:05AM  
Aug-06-19 05:52PM  
12:55PM  
10:30AM  
Aug-03-19 11:05AM  
Aug-01-19 01:15PM  
Jul-30-19 09:25PM  
Jul-29-19 01:15PM  
Jul-26-19 11:40PM  
Jul-25-19 03:09PM  
Jun-07-19 12:00PM  
May-31-19 01:33PM  
May-24-19 06:00AM  
May-15-19 04:00PM  
May-09-19 10:55AM  
07:00AM  
Apr-24-19 07:00AM  
Apr-01-19 07:00AM  
Mar-04-19 07:00AM  
Feb-21-19 09:01AM  
Feb-04-19 04:21PM  
Jan-16-19 04:50PM  
Jan-10-19 06:00AM  
Jan-04-19 07:00AM  
Dec-21-18 07:00AM  
Dec-18-18 04:01PM  
Dec-17-18 07:00AM  
Nov-20-18 07:00AM  
Nov-13-18 06:30AM  
Sep-19-18 03:43PM  
Aug-30-18 09:59AM  
Aug-14-18 07:00AM  
Jul-30-18 02:24PM  
Jul-03-18 06:23AM  
Jun-21-18 07:00AM  
Jun-20-18 10:01PM  
08:00AM  
Jun-18-18 03:31PM  
Jun-12-18 07:00AM  
Jun-11-18 05:07PM  
Jun-08-18 07:10AM  
Jun-07-18 04:42PM  
May-29-18 05:00PM  
May-21-18 07:25AM  
May-15-18 04:01PM  
Apr-23-18 04:30PM  
Apr-18-18 09:00PM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and the Merck Sharp & Dohme Corp. to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 14, 10% OwnerMay 20Sale3.66420,0001,535,5622,892,877May 22 04:56 PM
Goater JeffChief Executive OfficerFeb 05Buy3.235,00016,150262,000Feb 07 04:05 PM
MRSN Mersana Therapeutics, Inc. daily Stock Chart
MRSN [NASD]
Mersana Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own0.80% Shs Outstand47.99M Perf Week1.96%
Market Cap1.37B Forward P/E- EPS next Y-1.27 Insider Trans- Shs Float45.17M Perf Month-10.27%
Income-67.00M PEG- EPS next Q-0.30 Inst Own61.90% Short Float10.08% Perf Quarter106.63%
Sales1.10M P/S1245.87 EPS this Y76.80% Inst Trans2.53% Short Ratio2.39 Perf Half Y207.59%
Book/sh1.31 P/B15.47 EPS next Y8.20% ROA-57.70% Target Price27.00 Perf Year541.46%
Cash/sh1.16 P/C17.46 EPS next 5Y- ROE-78.20% 52W Range1.32 - 24.97 Perf YTD253.75%
Dividend- P/FCF- EPS past 5Y- ROI-36.10% 52W High-18.82% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low1435.61% ATR1.41
Employees83 Current Ratio4.60 Sales Q/Q-100.00% Oper. Margin- RSI (14)45.89 Volatility5.39% 6.76%
OptionableYes Debt/Eq0.08 EPS Q/Q-150.70% Profit Margin- Rel Volume0.35 Prev Close20.47
ShortableYes LT Debt/Eq0.06 EarningsAug 07 BMO Payout- Avg Volume1.90M Price20.27
Recom1.30 SMA20-4.21% SMA50-4.69% SMA200101.03% Volume671,430 Change-0.98%
Apr-29-20Initiated BTIG Research Buy $14
Jan-21-20Reiterated H.C. Wainwright Buy $7 → $12
Mar-11-19Downgrade JP Morgan Neutral → Underweight
Nov-14-18Upgrade Leerink Partners Mkt Perform → Outperform
May-08-18Initiated Robert W. Baird Outperform
Mar-19-18Downgrade JP Morgan Overweight → Neutral
Aug-07-20 07:17AM  
06:00AM  
Aug-06-20 04:13PM  
Aug-04-20 12:19PM  
08:00AM  
07:30AM  
Jul-31-20 08:00AM  
Jul-09-20 05:40AM  
Jul-08-20 04:15PM  
Jul-01-20 09:40AM  
Jun-30-20 06:56AM  
Jun-26-20 07:50AM  
Jun-24-20 12:27PM  
Jun-22-20 09:05AM  
Jun-08-20 01:25PM  
Jun-04-20 08:30AM  
08:00AM  
Jun-02-20 05:24PM  
10:22AM  
Jun-01-20 08:34AM  
May-29-20 10:29AM  
May-28-20 11:25PM  
05:00PM  
10:04AM  
09:42AM  
08:55AM  
06:00AM  
May-27-20 06:33PM  
11:39AM  
11:20AM  
06:00AM  
May-20-20 07:28AM  
May-15-20 08:00AM  
07:00AM  
May-14-20 04:05PM  
May-13-20 05:00PM  
09:49AM  
08:00AM  
May-12-20 08:04AM  
May-11-20 06:52AM  
May-09-20 11:30PM  
May-08-20 07:56AM  
06:00AM  
May-04-20 12:24PM  
Apr-29-20 04:05PM  
Apr-24-20 08:30PM  
08:47AM  
Apr-20-20 09:06AM  
07:52AM  
Apr-15-20 08:00AM  
Apr-14-20 09:13AM  
Apr-10-20 01:49PM  
Apr-08-20 07:53AM  
Apr-07-20 10:07PM  
Mar-30-20 04:01PM  
Mar-20-20 08:00AM  
Mar-03-20 07:07AM  
Feb-28-20 06:00AM  
Feb-21-20 08:00AM  
Feb-18-20 08:00AM  
Jan-21-20 08:57AM  
Jan-10-20 08:00AM  
Jan-02-20 08:00AM  
Dec-13-19 01:54PM  
Dec-06-19 09:47AM  
Nov-08-19 08:00AM  
Nov-06-19 06:00AM  
Oct-30-19 08:00AM  
Oct-11-19 12:44PM  
Sep-27-19 08:00AM  
Aug-28-19 08:00AM  
Aug-20-19 08:00AM  
Aug-12-19 03:43PM  
Aug-08-19 06:00AM  
Aug-06-19 08:00AM  
Aug-01-19 08:00AM  
Jul-05-19 12:29PM  
Jul-04-19 12:07PM  
Jun-12-19 08:00AM  
Jun-01-19 09:00AM  
May-30-19 08:00AM  
May-20-19 08:00AM  
May-16-19 11:14PM  
May-09-19 06:00AM  
May-02-19 08:00AM  
Apr-29-19 01:25PM  
Apr-09-19 08:15AM  
Apr-01-19 08:00AM  
Mar-25-19 08:00AM  
Mar-12-19 11:02AM  
Mar-11-19 02:33PM  
Mar-08-19 06:00AM  
Mar-06-19 08:00AM  
Mar-05-19 04:01PM  
Mar-01-19 04:01PM  
08:50AM  
07:00AM  
Feb-28-19 04:03PM  
Feb-20-19 08:00AM  
Jan-10-19 06:52AM  
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mandelia AshishVP, ControllerJul 02Sale22.493,38376,0840Jul 06 04:15 PM
Alleva Lawrence MDirectorJun 01Buy22.951,08524,9011,085Jun 03 05:30 PM
SANDELL SCOTT D10% OwnerApr 14Sale9.225485,0530Apr 14 05:54 PM
SANDELL SCOTT D10% OwnerApr 13Sale8.981,65014,8120Apr 14 05:54 PM
BASKETT FOREST10% OwnerApr 13Sale8.583,19027,3580Apr 14 05:54 PM
SANDELL SCOTT D10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:10 PM
BASKETT FOREST10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:06 PM
Florence Anthony A. Jr.10% OwnerApr 13Sale8.5020,914177,7750Apr 13 09:06 PM
Hack Andrew A. F.DirectorApr 07Buy5.993,445,66720,649,4633,445,667Apr 09 04:11 PM
MOTT DAVID MDirectorApr 07Buy5.59538,5993,010,768538,599Apr 09 03:31 PM
New Enterprise Associates 14, 10% OwnerAug 28Sale2.911,2113,52411,959,520Apr 13 08:39 PM
IMRA IMARA Inc. daily Stock Chart
IMRA [NASD]
IMARA Inc.
Index- P/E- EPS (ttm)-5.48 Insider Own13.50% Shs Outstand17.28M Perf Week1.34%
Market Cap347.00M Forward P/E- EPS next Y-2.88 Insider Trans0.00% Shs Float3.94M Perf Month-11.16%
Income-34.30M PEG- EPS next Q-0.56 Inst Own70.00% Short Float3.44% Perf Quarter-10.46%
Sales- P/S- EPS this Y-107.00% Inst Trans11.85% Short Ratio1.58 Perf Half Y-
Book/sh30.11 P/B0.68 EPS next Y22.00% ROA- Target Price- Perf Year-
Cash/sh6.24 P/C3.28 EPS next 5Y- ROE- 52W Range13.40 - 62.71 Perf YTD36.40%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.37% Beta-
Dividend %- Quick Ratio22.20 Sales past 5Y- Gross Margin- 52W Low52.69% ATR1.55
Employees16 Current Ratio22.20 Sales Q/Q- Oper. Margin- RSI (14)34.29 Volatility4.47% 7.56%
OptionableNo Debt/Eq0.00 EPS Q/Q-530.80% Profit Margin- Rel Volume0.10 Prev Close20.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume86.01K Price20.46
Recom2.00 SMA20-1.07% SMA50-34.27% SMA200-17.59% Volume8,935 Change1.89%
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
07:00AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
CSBR Champions Oncology, Inc. daily Stock Chart
CSBR [NASD]
Champions Oncology, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own7.00% Shs Outstand12.42M Perf Week2.52%
Market Cap112.54M Forward P/E38.45 EPS next Y0.23 Insider Trans-44.57% Shs Float10.26M Perf Month-4.38%
Income-2.00M PEG- EPS next Q0.02 Inst Own49.50% Short Float1.55% Perf Quarter-0.33%
Sales32.10M P/S3.51 EPS this Y157.10% Inst Trans-4.68% Short Ratio2.84 Perf Half Y23.59%
Book/sh0.43 P/B20.84 EPS next Y180.72% ROA-12.50% Target Price11.00 Perf Year46.64%
Cash/sh0.66 P/C13.56 EPS next 5Y15.00% ROE-64.00% 52W Range4.02 - 10.89 Perf YTD7.56%
Dividend- P/FCF160.77 EPS past 5Y40.30% ROI-35.80% 52W High-17.72% Beta1.31
Dividend %- Quick Ratio1.10 Sales past 5Y29.40% Gross Margin47.40% 52W Low122.89% ATR0.50
Employees143 Current Ratio1.10 Sales Q/Q13.00% Oper. Margin-6.00% RSI (14)47.32 Volatility3.69% 5.65%
OptionableNo Debt/Eq0.02 EPS Q/Q-655.30% Profit Margin-6.10% Rel Volume0.26 Prev Close8.84
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume55.87K Price8.96
Recom2.00 SMA20-2.04% SMA50-3.49% SMA20017.97% Volume14,391 Change1.36%
Nov-18-19Initiated The Benchmark Company Speculative Buy
Jul-30-20 07:21AM  
Jul-27-20 04:01PM  
Jul-22-20 08:00AM  
Jul-15-20 03:55PM  
Jun-17-20 09:37AM  
May-27-20 07:05AM  
Apr-28-20 09:50AM  
Apr-27-20 07:20AM  
Mar-28-20 09:23AM  
Mar-16-20 09:35AM  
Mar-12-20 04:17PM  
Mar-10-20 08:30AM  
Feb-26-20 09:32AM  
Feb-18-20 05:44AM  
Feb-05-20 09:23AM  
Jan-29-20 09:00AM  
Jan-17-20 09:34AM  
Jan-13-20 06:07AM  
Dec-24-19 09:37AM  
Dec-16-19 04:00PM  
Dec-09-19 08:30AM  
Dec-08-19 08:59AM  
Dec-04-19 08:36AM  
Nov-14-19 08:53AM  
Nov-13-19 05:00PM  
Nov-12-19 07:27AM  
Oct-24-19 09:00AM  
Oct-18-19 07:41AM  
Oct-03-19 08:49AM  
Sep-25-19 12:43PM  
Sep-16-19 04:00PM  
02:30PM  
Sep-13-19 08:39AM  
Sep-09-19 08:30AM  
Sep-02-19 01:30PM  
Aug-26-19 08:37AM  
Aug-05-19 08:42AM  
Jul-29-19 06:48PM  
Jul-26-19 06:58AM  
Jul-15-19 04:35PM  
Jul-12-19 10:00AM  
Jul-02-19 09:35AM  
May-31-19 09:37AM  
May-30-19 08:30AM  
May-01-19 08:07AM  
Apr-17-19 09:49AM  
Apr-16-19 10:51AM  
Apr-01-19 08:54AM  
Mar-27-19 10:03AM  
Mar-25-19 10:42AM  
Mar-18-19 04:00PM  
Mar-06-19 08:30AM  
Mar-04-19 11:40PM  
Jan-10-19 08:43AM  
Dec-17-18 03:30PM  
03:00PM  
Dec-10-18 04:30PM  
Nov-22-18 05:45PM  
Nov-16-18 05:45PM  
Nov-15-18 07:20AM  
Nov-07-18 08:30AM  
Nov-05-18 05:45PM  
Nov-02-18 07:27AM  
Oct-29-18 09:30AM  
Oct-23-18 05:45PM  
Oct-12-18 09:30AM  
Oct-04-18 06:55AM  
Oct-01-18 12:10PM  
Sep-28-18 09:15AM  
Sep-21-18 10:00AM  
Sep-20-18 09:15AM  
Sep-13-18 04:05PM  
08:30AM  
Sep-06-18 10:59AM  
Aug-28-18 08:30AM  
Aug-08-18 08:30AM  
Jul-26-18 04:02PM  
Jul-12-18 08:30AM  
Jun-18-18 08:30AM  
May-03-18 08:30AM  
May-01-18 08:30AM  
Apr-04-18 08:30AM  
Mar-28-18 07:10AM  
Mar-15-18 04:01PM  
12:45PM  
08:46AM  
Mar-07-18 08:30AM  
Feb-27-18 07:19PM  
Feb-26-18 08:30AM  
Feb-21-18 08:30AM  
Feb-14-18 06:29PM  
Dec-29-17 05:45PM  
Dec-19-17 09:16AM  
Dec-18-17 07:40AM  
Dec-07-17 04:15PM  
06:23AM  
Nov-28-17 08:05AM  
Nov-27-17 04:01PM  
05:50AM  
Nov-07-17 08:00AM  
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mendelson Daniel NewmanDirectorMar 26Buy5.911,2207,21358,746Mar 30 04:56 PM
Mendelson Daniel NewmanDirectorMar 24Buy5.502614357,526Mar 26 03:00 PM
Morris RonnieCEOMar 24Sale5.2575394837,168Mar 26 02:52 PM
Morris RonnieCEOMar 20Buy4.7575356837,243Mar 24 09:54 AM
New Enterprise Associates 14, 10% OwnerMar 06Sale6.99708,1554,950,0031,713,720Mar 10 04:45 PM
ACKERMAN JOELDirectorDec 02Option Exercise2.10203,111426,5331,316,988Dec 04 04:10 PM
CSPR Casper Sleep Inc. daily Stock Chart
CSPR [NYSE]
Casper Sleep Inc.
Index- P/E- EPS (ttm)-1.93 Insider Own8.60% Shs Outstand27.91M Perf Week-5.31%
Market Cap345.23M Forward P/E- EPS next Y-1.68 Insider Trans0.00% Shs Float26.71M Perf Month6.33%
Income-110.10M PEG- EPS next Q-0.76 Inst Own38.30% Short Float6.72% Perf Quarter21.90%
Sales462.90M P/S0.75 EPS this Y0.20% Inst Trans0.19% Short Ratio5.53 Perf Half Y-20.90%
Book/sh2.50 P/B3.50 EPS next Y39.60% ROA- Target Price8.61 Perf Year-
Cash/sh2.94 P/C2.97 EPS next 5Y17.80% ROE- 52W Range3.15 - 15.85 Perf YTD-35.26%
Dividend- P/FCF- EPS past 5Y- ROI30.50% 52W High-44.86% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin48.60% 52W Low177.46% ATR0.59
Employees597 Current Ratio1.60 Sales Q/Q26.40% Oper. Margin- RSI (14)54.83 Volatility7.80% 7.18%
OptionableYes Debt/Eq0.23 EPS Q/Q26.30% Profit Margin- Rel Volume0.71 Prev Close8.70
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume324.41K Price8.74
Recom2.10 SMA207.28% SMA504.57% SMA20017.14% Volume229,685 Change0.46%
Mar-02-20Initiated UBS Neutral $10
Mar-02-20Initiated Piper Sandler Overweight $15
Mar-02-20Initiated Morgan Stanley Equal-Weight $12
Mar-02-20Initiated Jefferies Buy $19
Mar-02-20Initiated Guggenheim Buy $16
Mar-02-20Initiated Goldman Buy $16
Mar-02-20Initiated Citigroup Buy $12
Aug-08-20 10:00PM  
Aug-07-20 07:15PM  
12:00PM  
Aug-06-20 01:40PM  
12:30PM  
12:23PM  
10:48AM  
06:20AM  
Aug-05-20 09:30PM  
03:35PM  
Aug-04-20 12:30PM  
10:20AM  
09:48AM  
06:20AM  
Aug-03-20 11:30PM  
08:36PM  
08:35PM  
12:16PM  
06:20AM  
Aug-02-20 10:34AM  
10:00AM  
Aug-01-20 07:00PM  
Jul-30-20 08:00PM  
02:45PM  
02:22PM  
06:45AM  
Jul-29-20 11:00PM  
04:30PM  
Jul-28-20 06:30AM  
Jul-27-20 03:35PM  
02:55PM  
11:30AM  
10:15AM  
09:34AM  
Jul-24-20 06:25PM  
05:24PM  
03:15PM  
02:30PM  
11:30AM  
Jul-23-20 01:30PM  
01:30PM  
11:25AM  
10:22AM  
Jul-22-20 02:50PM  
12:27PM  
09:35AM  
Jul-21-20 03:25PM  
01:35PM  
06:20AM  
Jul-20-20 11:30PM  
06:20AM  
Jul-18-20 09:50PM  
Jul-17-20 01:25PM  
12:05PM  
11:50AM  
11:45AM  
11:00AM  
Jul-16-20 07:28PM  
05:40PM  
11:45AM  
11:00AM  
Jul-15-20 07:45PM  
06:45PM  
05:00PM  
02:54PM  
01:25PM  
09:10AM  
08:34AM  
Jul-14-20 04:44PM  
03:11PM  
12:40PM  
12:00PM  
06:20AM  
Jul-13-20 11:20PM  
11:20PM  
03:20PM  
03:00PM  
02:31PM  
01:30AM  
Jul-12-20 02:00PM  
Jul-11-20 04:40PM  
Jul-10-20 03:20PM  
02:45PM  
11:45AM  
11:00AM  
Jul-09-20 09:03PM  
03:00PM  
12:55PM  
12:27PM  
11:35AM  
11:00AM  
Jul-08-20 07:27PM  
07:24PM  
06:16AM  
Jul-07-20 11:30PM  
08:10PM  
07:00PM  
02:35PM  
02:00PM  
11:10AM  
Casper Sleep Inc., together with its subsidiaries, designs and sells sleep products to consumers in the United States, Canada, and Europe. It offers a range of Casper mattresses, pillows, sheets, duvets, bedroom furniture, sleep accessories, sleep technology, and other sleep-centric products and services. As of December 31, 2019, the company distributed its products through its e-commerce platform, 60 Casper retail stores, and 18 retail partners. The company was formerly known as Providence Mattress Company and changed its name to Casper Sleep Inc. in January 2014. Casper Sleep Inc. was incorporated in 2013 and is headquartered in New York, New York.
GRTX Galera Therapeutics, Inc. daily Stock Chart
GRTX [NASD]
Galera Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.64 Insider Own15.06% Shs Outstand24.82M Perf Week14.37%
Market Cap187.38M Forward P/E- EPS next Y-2.41 Insider Trans-23.52% Shs Float21.80M Perf Month8.30%
Income-65.20M PEG- EPS next Q-0.76 Inst Own69.50% Short Float0.58% Perf Quarter-31.97%
Sales- P/S- EPS this Y-96.20% Inst Trans1.29% Short Ratio1.73 Perf Half Y-41.17%
Book/sh2.14 P/B3.72 EPS next Y13.60% ROA- Target Price- Perf Year-
Cash/sh5.12 P/C1.56 EPS next 5Y57.80% ROE- 52W Range5.58 - 19.50 Perf YTD-39.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.18% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low42.65% ATR0.58
Employees32 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)52.69 Volatility8.64% 7.44%
OptionableNo Debt/Eq1.21 EPS Q/Q-46.30% Profit Margin- Rel Volume0.20 Prev Close7.55
ShortableYes LT Debt/Eq1.21 EarningsMay 12 BMO Payout- Avg Volume73.50K Price7.96
Recom1.50 SMA202.89% SMA50-4.81% SMA200-29.34% Volume14,709 Change5.43%
Dec-02-19Initiated Credit Suisse Neutral
Dec-02-19Initiated Citigroup Buy
Dec-02-19Initiated BTIG Research Buy
Dec-02-19Initiated BofA/Merrill Buy
Jul-30-20 08:00AM  
Jul-22-20 02:35PM  
Jul-13-20 05:46PM  
Jun-10-20 02:55PM  
May-29-20 08:00AM  
May-18-20 04:05PM  
May-13-20 05:19PM  
May-12-20 07:00AM  
May-05-20 08:00AM  
Apr-30-20 04:15PM  
Apr-02-20 08:00AM  
Mar-10-20 07:00AM  
Feb-27-20 04:05PM  
Feb-24-20 08:00AM  
Feb-19-20 08:00AM  
Jan-07-20 04:40PM  
Dec-17-19 08:00AM  
Dec-10-19 07:00AM  
Dec-05-19 05:18PM  
Dec-02-19 01:10PM  
Nov-06-19 07:26PM  
Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 19Sale8.251,001,3128,260,8242,467,961Jun 22 04:52 PM
Novartis Bioventures LtdFormer 10% OwnerJun 18Sale9.049008,1363,469,273Jun 22 04:52 PM
Novartis Bioventures Ltd10% OwnerJun 17Sale9.274,62242,8463,470,173Jun 17 05:47 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale9.308,60079,9803,474,795Jun 17 05:47 PM
Novartis Bioventures Ltd10% OwnerJun 15Sale9.056,16455,7843,483,395Jun 17 05:47 PM
Novartis Bioventures Ltd10% OwnerJun 12Sale9.191,50013,7853,489,559Jun 12 06:33 PM
Novartis Bioventures Ltd10% OwnerJun 11Sale9.217,20066,3123,491,059Jun 12 06:33 PM
Novartis Bioventures Ltd10% OwnerJun 10Sale9.468,53280,7133,498,259Jun 12 06:33 PM
Novartis Bioventures Ltd10% OwnerJun 09Sale9.387,00065,6603,506,791Jun 09 08:02 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale9.665,65954,6663,513,791Jun 09 08:02 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale9.668,65283,5783,519,450Jun 09 08:02 PM
Novartis Bioventures Ltd10% OwnerJun 04Sale9.554,08839,0403,528,102Jun 04 05:36 PM
Novartis Bioventures Ltd10% OwnerJun 03Sale9.785,20850,9343,532,190Jun 04 05:36 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale9.685,66954,8763,537,398Jun 04 05:36 PM
HOLMLUND JON TChief Medical OfficerMay 26Option Exercise1.07692740692May 28 04:50 PM
HOLMLUND JON TChief Medical OfficerMay 26Sale12.006928,3040May 28 04:50 PM
HOLMLUND JON TChief Medical OfficerMay 21Option Exercise1.071,1741,2561,174May 22 05:20 PM
HOLMLUND JON TChief Medical OfficerMay 21Sale12.001,17414,0880May 22 05:20 PM
HOLMLUND JON TChief Medical OfficerMay 20Option Exercise1.079691,037969May 22 05:20 PM
HOLMLUND JON TChief Medical OfficerMay 20Sale12.0096911,6280May 22 05:20 PM
HOLMLUND JON TChief Medical OfficerMay 12Option Exercise1.07671718671May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 12Sale12.006718,0520May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 11Option Exercise1.07185198185May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 11Sale12.001852,2200May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 08Option Exercise1.075,1025,4595,102May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 08Sale12.005,10261,2240May 12 07:00 PM
HOLMLUND JON TChief Medical OfficerMay 07Option Exercise1.072,0592,2032,059May 07 07:12 PM
HOLMLUND JON TChief Medical OfficerMay 07Sale12.002,05924,7090May 07 07:12 PM
HOLMLUND JON TChief Medical OfficerMay 06Option Exercise1.071,4891,5931,489May 07 07:12 PM
HOLMLUND JON TChief Medical OfficerMay 06Sale12.001,48917,8680May 07 07:12 PM
HOLMLUND JON TChief Medical OfficerMay 05Option Exercise1.073,0643,2783,064May 07 07:12 PM
HOLMLUND JON TChief Medical OfficerMay 05Sale12.163,06437,2580May 07 07:12 PM
OYST Oyster Point Pharma, Inc. daily Stock Chart
OYST [NASD]
Oyster Point Pharma, Inc.
Index- P/E- EPS (ttm)-2.89 Insider Own1.30% Shs Outstand23.44M Perf Week12.83%
Market Cap639.58M Forward P/E- EPS next Y-3.68 Insider Trans0.00% Shs Float22.05M Perf Month-5.47%
Income-63.20M PEG- EPS next Q-0.67 Inst Own84.50% Short Float2.89% Perf Quarter-25.37%
Sales- P/S- EPS this Y-167.20% Inst Trans6.93% Short Ratio4.67 Perf Half Y-21.52%
Book/sh9.42 P/B2.68 EPS next Y-36.80% ROA-43.20% Target Price- Perf Year-
Cash/sh8.95 P/C2.82 EPS next 5Y- ROE-60.50% 52W Range13.26 - 41.37 Perf YTD3.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.99% Beta-
Dividend %- Quick Ratio26.30 Sales past 5Y- Gross Margin- 52W Low90.35% ATR1.68
Employees30 Current Ratio26.30 Sales Q/Q- Oper. Margin- RSI (14)48.94 Volatility9.08% 6.64%
OptionableNo Debt/Eq0.00 EPS Q/Q-26.80% Profit Margin- Rel Volume0.17 Prev Close25.46
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume136.41K Price25.24
Recom2.00 SMA202.50% SMA50-7.66% SMA200-8.06% Volume22,663 Change-0.86%
Nov-25-19Initiated Piper Jaffray Overweight $35
Nov-25-19Initiated JP Morgan Overweight $26
Nov-25-19Initiated Cowen Outperform $40
Aug-05-20 07:00AM  
Jul-31-20 04:01PM  
Jun-01-20 11:39AM  
May-28-20 09:07AM  
May-24-20 12:25PM  
May-19-20 06:08PM  
May-15-20 02:02AM  
May-12-20 04:20PM  
May-11-20 10:31PM  
06:05AM  
06:00AM  
May-04-20 04:05PM  
Mar-30-20 07:30AM  
Feb-27-20 04:01PM  
Feb-24-20 08:00AM  
08:00AM  
Jan-12-20 08:00PM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-17-19 08:00AM  
Dec-03-19 03:29PM  
07:00AM  
Nov-25-19 08:00AM  
Nov-22-19 05:12PM  
Nov-05-19 09:10AM  
Oct-28-19 08:20AM  
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nau JeffreyPresident and CEOJul 28Option Exercise1.025,0005,1005,000Jul 30 07:37 PM
ADAP Adaptimmune Therapeutics plc daily Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.27 Insider Own0.10% Shs Outstand123.29M Perf Week-14.65%
Market Cap1.21B Forward P/E- EPS next Y-0.96 Insider Trans-81.31% Shs Float31.76M Perf Month-14.29%
Income-137.90M PEG- EPS next Q-0.25 Inst Own70.10% Short Float11.82% Perf Quarter79.73%
Sales1.90M P/S638.90 EPS this Y-33.20% Inst Trans12.05% Short Ratio1.14 Perf Half Y95.59%
Book/sh1.51 P/B5.28 EPS next Y-16.80% ROA-60.30% Target Price12.83 Perf Year303.03%
Cash/sh1.29 P/C6.18 EPS next 5Y1.00% ROE-85.60% 52W Range0.71 - 13.40 Perf YTD565.00%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-113.30% 52W High-40.45% Beta2.18
Dividend %- Quick Ratio7.60 Sales past 5Y-30.30% Gross Margin- 52W Low1025.53% ATR0.61
Employees400 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)33.94 Volatility6.35% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q12.80% Profit Margin- Rel Volume0.27 Prev Close8.06
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume3.29M Price7.98
Recom2.40 SMA20-10.97% SMA50-17.18% SMA20079.35% Volume875,534 Change-0.99%
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
08:52AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
12:38AM  
Jun-01-20 09:39PM  
12:51PM  
11:01AM  
09:38AM  
06:09AM  
06:00AM  
04:15AM  
May-29-20 05:08PM  
02:20PM  
10:32AM  
10:24AM  
07:30AM  
May-19-20 07:02AM  
May-14-20 12:00PM  
08:55AM  
07:30AM  
May-12-20 08:00AM  
06:07AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
08:00AM  
Mar-20-20 10:40PM  
Mar-11-20 11:35AM  
Feb-29-20 08:31AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-24-20 03:15PM  
Feb-20-20 04:00PM  
Feb-18-20 08:00AM  
Feb-07-20 04:05PM  
Feb-05-20 11:30AM  
Feb-03-20 09:13AM  
Jan-24-20 04:30PM  
Jan-22-20 01:18PM  
08:48AM  
08:25AM  
06:48AM  
Jan-21-20 04:08PM  
Jan-17-20 12:00PM  
Jan-15-20 08:22AM  
Jan-14-20 12:29PM  
07:55AM  
02:08AM  
Jan-13-20 08:30AM  
02:00AM  
Dec-30-19 05:25AM  
Dec-16-19 05:45AM  
Dec-03-19 02:20PM  
08:30AM  
Nov-17-19 11:40AM  
Nov-16-19 02:00AM  
Nov-06-19 07:30AM  
Nov-01-19 08:00AM  
Oct-31-19 01:52PM  
06:09AM  
Oct-09-19 08:00AM  
Oct-01-19 08:00AM  
Sep-30-19 08:45AM  
Sep-16-19 06:41AM  
Sep-10-19 09:01AM  
Sep-09-19 08:00AM  
Aug-27-19 02:11PM  
08:00AM  
Aug-16-19 11:23AM  
Aug-01-19 10:24PM  
07:15AM  
07:15AM  
Jul-29-19 04:05PM  
Jul-25-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 11:00AM  
08:00AM  
Jul-09-19 11:23AM  
09:00AM  
Jun-29-19 05:37PM  
Jun-27-19 02:54PM  
08:00AM  
May-28-19 10:14AM  
May-15-19 12:28PM  
08:00AM  
May-06-19 07:30AM  
07:00AM  
May-02-19 07:00AM  
May-01-19 08:00AM  
Apr-18-19 04:01PM  
Apr-12-19 03:26PM  
Apr-02-19 08:00AM  
Apr-01-19 08:00AM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TAYTON-MARTIN HELEN KATRINAChief Business OfficerAug 03Sale8.74200,0001,748,1800Aug 04 09:02 PM
Lunger JohnChief Patient Supply OfficerAug 03Sale9.254,82344,6138,066Aug 04 09:02 PM
Rawcliffe AdrianChief Executive OfficerAug 03Sale9.252,78825,7893,064Aug 04 09:01 PM
Wood GavinChief Financial OfficerJun 29Buy1.6233,00053,46033,000Jun 30 09:01 PM
Alleva Lawrence MDirectorJun 09Buy1.8912,90024,38112,900Jun 11 09:00 PM
Noble JamesDirectorMay 29Sale9.33500,0004,666,0000Jun 02 09:30 PM
Sonsini Peter W.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:55 PM
SANDELL SCOTT D10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:54 PM
Florence Anthony A. Jr.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
MOTT DAVID MDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:53 PM
BASKETT FOREST10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:51 PM
Behbahani AliDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
Norry ElliotChief Medical OfficerJan 14Sale5.139114,6781,326Jan 15 08:03 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.132,39712,3083,605Jan 15 08:03 PM
Rawcliffe AdrianChief Executive OfficerJan 14Sale5.133,23616,6163,166Jan 15 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 14Sale5.131,1445,8741,681Jan 15 08:02 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerJan 13Sale4.50100,000450,0000Jan 15 08:02 PM
Noble JamesDirectorJan 13Sale4.67300,0001,400,0000Jan 15 08:01 PM
Rawcliffe AdrianChief Executive OfficerJan 06Sale1.205,9007,0805,804Jan 07 08:00 PM
Bertrand William C JRChief Operating OfficerJan 06Sale1.203,7314,4775,632Jan 07 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 06Sale1.201,1481,3781,677Jan 07 08:01 PM